The bill would expand Medicare coverage for in-home intravenous immune globulin (IVIG) treatment to people diagnosed with chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy, starting January 1, 2027. It would also let the Secretary of Health and Human Services set different payment rates based on which condition the treatment is for. The bill was introduced in the House on February 7, 2025, and referred to committees for consideration.
If you have one of the two named conditions, the bill would make in-home IVIG administration eligible for Medicare coverage beginning January 1, 2027. The bill does not explain how to apply or what other coverage rules would apply.
The bill does not state specific costs or payment amounts. It allows payment rates to vary by the condition being treated, as determined by the Secretary through rulemaking.
No publicly available information.
No publicly available information.